KONEXBiotech & Pharma266470

BioInfra Life Science

₩89▼ 10.10%2026-11-18 close
Market Cap
₩2.5B
Turnover
₩942,278
Volume
10K
Shares out.
27.9M
PER
—
PBR
—
EPS
—
Dividend Yield
0.00%

PER, PBR and dividend yield are calculated from the latest confirmed results (EPS, BPS, dividend per share) and the current share price · Prices as of the 2026-11-18 close

01

Report overview

Serial losses amid a business pivot

Revenue rebounded and gross profit turned positive in 2025, but four straight years of net losses and reliance on external funding remain the core issues.

  1. 1

    On a 2025 basis, revenue reached 1,270,468 thousand KRW, up 572.21% from the prior year.

  2. 2

    Gross profit was 448,699 thousand KRW, turning positive from a 2024 gross loss of 78,263 thousand KRW.

  3. 3

    The 2025 operating loss of 1,388,462 thousand KRW and net loss of 2,596,899 thousand KRW extended a run of net losses that started in 2022.

  4. 4

    Three rights offerings in 2024 and an operating cash outflow of 1,377,215 thousand KRW in 2025 point to dependence on outside funding.

  5. 5

    Revenue has tilted toward cosmetics and ultrasound beauty devices, while diagnostic services and the anticancer and drug-delivery R&D sit as secondary pillars.

02

Business structure

BioInfra Life Science is an in-vitro diagnostics and drug-delivery R&D company founded in 2001 and listed on KONEX. Its business rests on three pillars: diagnostic testing services, an ultrasound and microbubble-based drug-delivery system platform, and anticancer therapeutics R&D.

In diagnostics, the company provides testing services through a diagnostic laboratory hospital channel. In December 2020 it started its skin drug-delivery business, launching a home-use ultrasound beauty device and functional cosmetics.

According to JobKorea's business analysis, cosmetics account for 58%, beauty devices and cosmetics for 42%, and research services for 1%, so revenue mix leans toward beauty and cosmetics. In 2025 the company pursued expansion into beauty and medical devices with the ultrasound beauty device launch.

In the United States it has a technology agreement with 20/20 Genesystems to deliver premium services. Competitively, diagnostic testing overlaps with large laboratory operators and beauty devices with large cosmetics and medical device makers, and the company is small in both markets.

The anticancer therapeutics and targeted drug-delivery platform are described as R&D-stage, so their current revenue contribution appears limited. The business is in a transition from diagnostics toward beauty and devices.

03

Recent trends

On a 2025 basis, revenue reached 1,270,468 thousand KRW, up 572.21% from the prior year, after about 189,000 thousand KRW in 2024. Gross profit in 2025 was 448,699 thousand KRW, turning positive from a 2024 gross loss of 78,263 thousand KRW.

The operating loss narrowed to 1,388,462 thousand KRW from 2,035,672 thousand KRW in 2024, though the operating margin stood at -109.29%. Non-operating income was 367,431 thousand KRW against non-operating expenses of 1,575,868 thousand KRW, so the net non-operating outflow widened the loss.

The net loss of 2,596,899 thousand KRW was smaller than the 3,108,446 thousand KRW recorded in 2024, yet the company has reported net losses every year from 2022 through 2025. Operating cash flow in 2025 was -1,377,215 thousand KRW and investing cash flow was -1,599,822 thousand KRW.

At year-end 2025, total assets were 2,603,099 thousand KRW and liabilities were 2,063,859 thousand KRW, with an equity ratio of 20.72%.

In 2024 the company completed rights offerings of 1.5 billion KRW in August, 1.5 billion KRW in October and 3.1 billion KRW in December, and its largest shareholder changed to Lee Jeong-ho in September.

The share price moved from 208 KRW on the August 25, 2025 close to 93 KRW on November 11, 2026 (up 4.49% from the prior day), and market capitalization is 2.6 billion KRW.

04

Outlook

The central question for future earnings is whether the revenue rebound is a one-off or turns into recurring sales in the beauty device and cosmetics business.

Gross profit turned positive on a 2025 basis, but an operating loss remains, so cost improvement alone is unlikely to show whether the company can reach break-even.

Sales performance after the 2025 ultrasound beauty device launch and the revenue scale from the US technology agreement can be checked in the 2026 annual business report. The anticancer therapeutics and the DDS platform are likely to contribute little to earnings until clinical or regulatory progress is disclosed.

The 2023 sales suspension by the Ministry of Food and Drug Safety shows that regulatory risk in diagnostics has materialized, so the outcome of related administrative proceedings and their effect on diagnostic sales need ongoing monitoring.

On the financial side, three rights offerings in 2024 and an equity ratio of 20.72% add to the need for further fundraising. Continuity of governance and business direction after the September 2024 change in the largest shareholder is also an item to confirm through disclosures.

At a market capitalization of 2.6 billion KRW, the share price can move sharply with trading conditions and does not by itself reflect business performance.

05

Bull factors

Revenue and gross profit rebound

On a 2025 basis, revenue rose 572.21% from a low 2024 base. Gross profit of 448,699 thousand KRW, after a 2024 gross loss, suggests an improved cost structure. The operating loss also narrowed from 2024, showing a directional improvement in the figures.

Ultrasound platform breadth

The ultrasound and microbubble targeted drug-delivery platform could extend beyond beauty devices into medical devices and anticancer applications. The technology agreement with 20/20 Genesystems serves as an overseas premium service channel. A corporate information site lists 12 patents for the company.

Regulatory track record in diagnostics

The company obtained a medical device manufacturing license in 2017 and acquired KGMP accreditation in February 2023. This record underpins its manufacturing capability for in-vitro diagnostic products.

It retains diagnostic testing services alongside multi-marker blood test software, keeping technical assets in the diagnostics business.

06

Bear factors

Four years of net losses and eroded equity

Net losses ran from 2022 through 2025, and equity was recorded as fully impaired in 2023. The 2025 operating loss was 1,388,462 thousand KRW, and non-operating expenses of 1,575,868 thousand KRW widened the net loss. The 2025 debt ratio of 382.73% signals a heavy financial burden.

Dependence on outside funding and cash outflows

Three rights offerings in 2024 made the reliance on external capital stand out. Operating cash flow in 2025 was -1,377,215 thousand KRW, so the operating loss translated into cash outflows. Investing cash flow in 2024 was -6,765,268 thousand KRW, reflecting large spending.

Regulatory sanction and limited scale

In May 2023 the Ministry of Food and Drug Safety imposed a sales suspension and disposal order on an in-vitro diagnostic software product, with an amount of 468.8 million KRW equal to 31.36% of recent sales. The company said it would respond through an objection, a preliminary injunction and an administrative lawsuit.

With a market capitalization of 2.6 billion KRW and headcount reported as either 3 or 5 depending on the source, the company's operating scale is small.

07

Risk factors

Macro

Interest rate levels and shifts in sentiment toward small-cap KOSDAQ and KONEX stocks can widen share price volatility. At a market capitalization of 2.6 billion KRW with small trading value, the stock can move sharply on modest order flow changes. Market conditions at the time of any fundraising will determine how heavily dilution weighs.

Regulatory

Diagnostic software has previously been at the center of a dispute over licensing scope, so sales could be restricted depending on how the regulator interprets the rules. The 2023 action shows that this business is exposed to regulatory change.

The effect of administrative outcomes on the diagnostics revenue base is a matter to track through future disclosures.

Funding and liquidity

On a 2025 basis, the equity ratio was 20.72% and the current ratio was 30.3%, leaving limited short-term liquidity headroom. Any further capital increase would dilute existing shareholders. If cash outflows continue, the company will depend more heavily on outside funding to sustain R&D.

08

Overall view

BioInfra Life Science posted improvement in operating indicators on a 2025 basis, with revenue rebounding and gross profit turning positive. However, four straight years of net losses from 2022, operating cash outflows and an equity ratio of 20.72% remain constraints on the financial side.

On the positive side, the ultrasound-based beauty device, the drug-delivery platform and the overseas technology agreement underpin business diversification.

On the negative side, three rights offerings in 2024, the 2023 sales suspension by the regulator and a market capitalization of 2.6 billion KRW add to uncertainty.

The share price moved from 208 KRW on August 25, 2025 to 93 KRW now, and this movement can be shaped by small-cap order flow and liquidity apart from business performance. At year-end 2025, liabilities of 2,063,859 thousand KRW made up a large share of total assets of 2,603,099 thousand KRW.

Whether the revenue rebound becomes recurring cannot be judged from current disclosures alone. The key checkpoints are therefore the revenue mix, the trend in operating losses and any additional fundraising in the 2026 annual business report.

09

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 8 more articles and sources
  1. comp.fnguide.com
  2. jobkorea.co.kr
  3. m.jobkorea.co.kr
  4. thevc.kr
  5. saramin.co.kr
  6. bioinfra.co.kr
  7. dailymedi.com
  8. m.healthcaren.com

Report written 2026-11-11 · Data as of 2026-11-10

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis